192 related articles for article (PubMed ID: 29655570)
1. Interleukin-7 enhances anti-tumor activity of CD8
Teng D; Ding L; Cai B; Luo Q; Wang H
Cytokine; 2019 Jun; 118():115-123. PubMed ID: 29655570
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-35 Dampens CD8
Yang L; Shao X; Jia S; Zhang Q; Jin Z
Front Immunol; 2019; 10():1032. PubMed ID: 31134088
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-35 Suppresses Interleukin-9-Secreting CD4
Zhang Q; Yang L; Liu S; Zhang M; Jin Z
Front Immunol; 2021; 12():645835. PubMed ID: 34177894
[TBL] [Abstract][Full Text] [Related]
4. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma.
Gehring AJ; Ho ZZ; Tan AT; Aung MO; Lee KH; Tan KC; Lim SG; Bertoletti A
Gastroenterology; 2009 Aug; 137(2):682-90. PubMed ID: 19394336
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-7 promotes CD8
Tian X; Su Z; Guo S; Wang C; Zhang X; Du J
Int Immunopharmacol; 2019 Oct; 75():105773. PubMed ID: 31349155
[TBL] [Abstract][Full Text] [Related]
6. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-35 suppresses the activity of natural killer-like B cells in patients with hepatocellular carcinoma.
Liu S; Yang L; Jia S; Zhao R; Jin Z
Int Immunopharmacol; 2021 Nov; 100():108161. PubMed ID: 34555643
[TBL] [Abstract][Full Text] [Related]
8. γδ T cells in hepatocellular carcinoma patients present cytotoxic activity but are reduced in potency due to IL-2 and IL-21 pathways.
Jiang H; Yang Z; Song Z; Green M; Song H; Shao Q
Int Immunopharmacol; 2019 May; 70():167-173. PubMed ID: 30802679
[TBL] [Abstract][Full Text] [Related]
9. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
10. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.
Langhans B; Nischalke HD; Krämer B; Dold L; Lutz P; Mohr R; Vogt A; Toma M; Eis-Hübinger AM; Nattermann J; Strassburg CP; Gonzalez-Carmona MA; Spengler U
Cancer Immunol Immunother; 2019 Dec; 68(12):2055-2066. PubMed ID: 31724091
[TBL] [Abstract][Full Text] [Related]
11. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8
Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH
Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359
[TBL] [Abstract][Full Text] [Related]
12. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma.
Huang CY; Wang Y; Luo GY; Han F; Li YQ; Zhou ZG; Xu GL
J Immunother; 2017; 40(9):323-333. PubMed ID: 29028787
[TBL] [Abstract][Full Text] [Related]
13. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
[TBL] [Abstract][Full Text] [Related]
14. [Effect of interleukin-7 on the anti-tumor function of CD8(+) T cells in patients with non-small cell lung cancer].
Zhang XH; Wang HM; Jin L; Chang R; Zu FC; Li FZ; Ku CY
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(30):2429-2433. PubMed ID: 30138989
[No Abstract] [Full Text] [Related]
15. Interleukin-7 augments CD8
Hou H; Kang Y; Zeng Y; Li Y; Shang J
Cytokine; 2018 Feb; 102():26-33. PubMed ID: 29275010
[TBL] [Abstract][Full Text] [Related]
16. Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients.
Kuang DM; Peng C; Zhao Q; Wu Y; Zhu LY; Wang J; Yin XY; Li L; Zheng L
J Immunol; 2010 Aug; 185(3):1544-9. PubMed ID: 20581151
[TBL] [Abstract][Full Text] [Related]
17. CD8
Xu C; Lu X; Liu W; Chen A; Meng G; Zhang H; Li B; Zhang Y; Wu J; Wei J
J Transl Med; 2018 May; 16(1):132. PubMed ID: 29784005
[TBL] [Abstract][Full Text] [Related]
18. PD1
Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
[TBL] [Abstract][Full Text] [Related]
19. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
20. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions.
Wu K; Kryczek I; Chen L; Zou W; Welling TH
Cancer Res; 2009 Oct; 69(20):8067-75. PubMed ID: 19826049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]